WAT
Neutral signalScored 2026-08-09 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Waters Corporation
- Nom
- Waters Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NYSE
- Capitalisation
- $44.5B
- Employés
- 7,900
- PDG
- Udit Batra
- Site web
- https://www.waters.com
- Marché
- ABRKRDHRHRIBFMKKGYMTD
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 3 626 titres (~1 442 930,44 $ US)
- Insiders
- KUEBLER CHRISTOPHER A
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,442,930
Avg sell (VWAP, 90d window) $397.94 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-06
- Last synced
-
2026-08-12 09:47:22
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-06 | KUEBLER CHRISTOPHER A | Sell · S | 3,626 | $397.94 | $1,442,930 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-03-10 | Thomas H. Kean | Sale | $1,001 - $15,000 |
| 2026-02-13 | Thomas H. Kean | Sale (Partial) | $1,001 - $15,000 |
| 2026-02-10 | Debbie Dingell | receive | $1,001 - $15,000 |
| 2026-02-09 | Kevin Hern | Exchange | $1,001 - $15,000 |
| 2025-12-08 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-09-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-13 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-12 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-07-16 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2024-11-19 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-08-04 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-09 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.73 · operating margin 28%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 57.8% | 59.4% | 59.6% | 58.0% | 58.5% | |
| Ebit Margin | 25.5% | 28.5% | 28.2% | 29.8% | 30.6% | |
| Ebitda Margin | 32.0% | 35.0% | 33.9% | 34.2% | 35.3% | |
| Operating Profit Margin | 28.2% | 27.9% | 27.7% | 29.4% | 29.5% | |
| Pretax Profit Margin | 23.8% | 25.5% | 24.9% | 28.2% | 28.9% | |
| Continuous Operations Profit Margin | 20.3% | 21.6% | 21.7% | 23.8% | 24.9% | |
| Net Profit Margin | 20.3% | 21.6% | 21.7% | 23.8% | 24.9% | |
| Bottom Line Profit Margin | 20.3% | 21.6% | 21.7% | 23.8% | 24.9% | |
| Current Ratio | 1.733 | 2.113 | 2.220 | 2.245 | 2.394 | |
| Quick Ratio | 1.271 | 1.509 | 1.566 | 1.665 | 1.870 | |
| Solvency Ratio | 0.337 | 0.304 | 0.232 | 0.302 | 0.302 | |
| Cash Ratio | 0.474 | 0.411 | 0.500 | 0.612 | 0.737 | |
| Price To Earnings Ratio | 35.169 | 34.510 | 30.288 | 29.032 | 33.120 | |
| Price To Earnings Growth Ratio | 75.614 | -31.260 | -3.843 | 5.938 | 0.976 | |
| Forward Price To Earnings Growth Ratio | 75.614 | -31.260 | -3.843 | 5.938 | 0.976 | |
| Price To Earnings Diluted Ratio | 35.300 | 34.639 | 30.372 | 29.205 | 33.357 | |
| Price To Earnings Diluted Growth Ratio | 75.613 | -28.883 | -4.003 | 5.825 | 0.992 | |
| Price To Book Ratio | 8.825 | 12.038 | 16.908 | 40.734 | 62.420 | |
| Price To Sales Ratio | 7.141 | 7.440 | 6.579 | 6.915 | 8.235 | |
| Price To Free Cash Flow Ratio | 41.873 | 35.523 | 43.986 | 47.990 | 39.624 | |
| Price To Operating Cash Flow Ratio | 34.638 | 28.882 | 32.265 | 33.596 | 30.702 | |
| Debt To Assets Ratio | 0.294 | 0.374 | 0.528 | 0.507 | 0.517 | |
| Debt To Equity Ratio | 0.582 | 0.931 | 2.123 | 3.297 | 4.357 | |
| Debt To Capital Ratio | 0.368 | 0.482 | 0.680 | 0.767 | 0.813 | |
| Long Term Debt To Capital Ratio | 0.270 | 0.471 | 0.667 | 0.751 | 0.805 | |
| Financial Leverage Ratio | 1.982 | 2.490 | 4.022 | 6.505 | 8.420 | |
| Working Capital Turnover Ratio | 3.542 | 3.211 | 3.046 | 3.085 | 3.608 | |
| Operating Cash Flow Ratio | 0.526 | 0.965 | 0.763 | 0.778 | 1.098 | |
| Operating Cash Flow Sales Ratio | 0.206 | 0.258 | 0.204 | 0.206 | 0.268 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.827 | 0.813 | 0.734 | 0.700 | 0.775 | |
| Debt Service Coverage Ratio | 1.699 | 10.252 | 6.093 | 8.978 | 19.348 | |
| Interest Coverage Ratio | 12.843 | 9.215 | 8.271 | 17.899 | 18.285 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.419 | 0.000 | 12.056 | 12.233 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.438 | 0.448 | 0.247 | 0.368 | 0.467 | |
| Capital Expenditure Coverage Ratio | 5.788 | 5.349 | 3.753 | 3.334 | 4.441 | |
| Dividend Paid And Capex Coverage Ratio | 5.788 | 5.349 | 3.753 | 3.334 | 4.441 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 23.230 | 22.568 | 21.475 | 21.368 | 24.464 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 57.8% | ▼-1.7% | ▼-0.9% |
| Ebit Margin | 25.4% | ▼-3.1% | ▼-3.1% |
| Ebitda Margin | 32.0% | ▼-3.1% | ▼-2.1% |
| Operating Profit Margin | 28.2% | ▲0.3% | ▼-0.3% |
| Pretax Profit Margin | 23.8% | ▼-1.7% | ▼-2.4% |
| Continuous Operations Profit Margin | 20.3% | ▼-1.3% | ▼-2.1% |
| Net Profit Margin | 20.3% | ▼-1.3% | ▼-2.1% |
| Bottom Line Profit Margin | 20.3% | ▼-1.3% | ▼-2.1% |
| Current Ratio | 1.733 | ▼-0.381 | ▼-0.408 |
| Quick Ratio | 1.271 | ▼-0.238 | ▼-0.305 |
| Solvency Ratio | 0.338 | ▲0.033 | ▲0.042 |
| Cash Ratio | 0.474 | ▲0.064 | ▼-0.072 |
| Price To Earnings Ratio | 35.169 | ▲0.660 | ▲2.746 |
| Price To Earnings Growth Ratio | 75.614 | ▲106.874 | ▲66.129 |
| Forward Price To Earnings Growth Ratio | 75.614 | ▲106.874 | ▲66.129 |
| Price To Earnings Diluted Ratio | 35.300 | ▲0.661 | ▲2.725 |
| Price To Earnings Diluted Growth Ratio | 75.613 | ▲104.496 | ▲65.704 |
| Price To Book Ratio | 8.825 | ▼-3.213 | ▼-19.360 |
| Price To Sales Ratio | 7.141 | ▼-0.299 | ▼-0.121 |
| Price To Free Cash Flow Ratio | 41.873 | ▲6.350 | ▲0.073 |
| Price To Operating Cash Flow Ratio | 34.638 | ▲5.756 | ▲2.622 |
| Debt To Assets Ratio | 0.294 | ▼-0.080 | ▼-0.150 |
| Debt To Equity Ratio | 0.582 | ▼-0.349 | ▼-1.676 |
| Debt To Capital Ratio | 0.368 | ▼-0.114 | ▼-0.254 |
| Long Term Debt To Capital Ratio | 0.270 | ▼-0.201 | ▼-0.323 |
| Financial Leverage Ratio | 1.982 | ▼-0.508 | ▼-2.702 |
| Working Capital Turnover Ratio | 3.542 | ▲0.331 | ▲0.243 |
| Operating Cash Flow Ratio | 0.526 | ▼-0.439 | ▼-0.300 |
| Operating Cash Flow Sales Ratio | 0.206 | ▼-0.051 | ▼-0.022 |
| Free Cash Flow Operating Cash Flow Ratio | 0.827 | ▲0.014 | ▲0.058 |
| Debt Service Coverage Ratio | 1.699 | ▼-8.553 | ▼-7.575 |
| Interest Coverage Ratio | 12.843 | ▲3.628 | ▼-0.459 |
| Short Term Operating Cash Flow Coverage Ratio | 1.419 | ▲1.419 | ▼-3.723 |
| Operating Cash Flow Coverage Ratio | 0.438 | ▼-0.010 | ▲0.044 |
| Capital Expenditure Coverage Ratio | 5.788 | ▲0.439 | ▲1.255 |
| Dividend Paid And Capex Coverage Ratio | 5.788 | ▲0.439 | ▲1.255 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 23.230 | ▲0.662 | ▲0.609 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $22.60B | $22.01B | $19.45B | $20.55B | $22.94B | |
| Enterprise value | $23.51B | $23.39B | $21.50B | $21.73B | $24.04B | |
| EV / Sales | 7.43x | 7.91x | 7.27x | 7.31x | 8.63x | |
| EV / Op. cash flow | 36.02x | 30.69x | 35.66x | 35.53x | 32.17x | |
| EV / Free cash flow | 43.55x | 37.75x | 48.62x | 50.75x | 41.52x | |
| EV / EBITDA | 23.23x | 22.57x | 21.48x | 21.37x | 24.46x | |
| Net debt / EBITDA | 0.89x | 1.33x | 2.04x | 1.16x | 1.12x | |
| Current ratio | 1.73x | 2.11x | 2.22x | 2.25x | 2.39x | |
| Income quality | 1.01x | 1.20x | 0.94x | 0.86x | 1.08x | |
| Graham number | $102 | $86 | $69 | $47 | $39 | |
| Graham net-net | -$17 | -$27 | -$39 | -$25 | -$25 | |
| Tax burden | 85.1% | 84.5% | 87.2% | 84.5% | 85.9% | |
| Interest burden | 93.7% | 89.4% | 88.2% | 94.5% | 94.7% | |
| Working capital | $908.1M | $879.4M | $963.3M | $978.2M | $948.4M | |
| Invested capital | $3.53B | $3.47B | $3.62B | $2.30B | $2.26B | |
| Return on assets | 12.7% | 14.0% | 13.9% | 21.6% | 22.4% | |
| Operating ROA | 18.6% | 18.0% | 20.7% | 27.4% | 27.7% | |
| Return on tangible assets | 20.2% | 23.7% | 23.9% | 27.0% | 28.7% | |
| Return on equity | 25.1% | 34.9% | 55.8% | 140.3% | 188.5% | |
| Return on invested capital | 17.6% | 18.4% | 18.2% | 28.7% | 28.9% | |
| Return on capital employed | 23.3% | 22.0% | 21.3% | 35.0% | 34.0% | |
| Earnings yield | 2.8% | 2.9% | 3.3% | 3.4% | 3.0% | |
| Free cash flow yield | 2.4% | 2.8% | 2.3% | 2.1% | 2.5% | |
| Capex / Op. cash flow | 17.3% | 18.7% | 26.6% | 30.0% | 22.5% | |
| Capex / Depreciation | 54.7% | 74.3% | 96.8% | 140.7% | 127.8% | |
| Capex / Sales | 3.6% | 4.8% | 5.4% | 6.2% | 6.0% | |
| SG&A / Sales | 23.4% | 23.3% | 24.9% | 22.1% | 22.5% | |
| R&D / Sales | 6.2% | 6.2% | 5.9% | 5.9% | 6.0% | |
| Stock comp / Sales | 1.7% | 1.5% | 1.2% | 1.4% | 1.1% | |
| Intangibles / Total assets | 37.4% | 40.9% | 41.8% | 20.0% | 22.0% | |
| Days sales outstanding | 96d | 90d | 87d | 89d | 80d | |
| Days payables outstanding | 28d | 30d | 26d | 27d | 31d | |
| Operating cycle | 252d | 236d | 244d | 222d | 193d | |
| Cash conversion cycle | 224d | 205d | 218d | 195d | 162d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-10 Dudley & Shanley Inc. Has $8.85 Million Stake in Waters Corporation $WAT Dudley and Shanley Inc. raised its holdings in Waters Corporation (NYSE: WAT) by 101.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,590 shares of the medical instruments supplier''s stock after purchasing an additional 11,870 shares during the period. Waters makes
- 2026-08-10 Waters (NYSE:WAT) Director Sells $1,442,930.44 in Stock Waters Corporation (NYSE: WAT - Get Free Report) Director Christopher Kuebler sold 3,626 shares of Waters stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the transaction, the director directly owned 17,808 shares in the company, valued
- 2026-08-09 Waters Q2 Earnings Call Highlights Waters NYSE: WAT reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business revenue and adjusted earnings per share after results exceeded its prior guidance.
- 2026-08-06 Waters Corporation $WAT Shares Acquired by Empowered Funds LLC Empowered Funds LLC lifted its stake in Waters Corporation (NYSE: WAT) by 431.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,954 shares of the medical instruments supplier''s stock after purchasing an additional 6,456 shares during the period. Empowered
- 2026-08-05 Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.
- 2026-08-05 Cetera Investment Advisers Grows Stock Holdings in Waters Corporation $WAT Cetera Investment Advisers increased its stake in Waters Corporation (NYSE: WAT) by 121.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,097 shares of the medical instruments supplier''s stock after buying an additional 7,172 shares during the period. Cetera Investment Advisers'' holdings
- 2026-08-04 Waters Corporation (WAT) Q2 2026 Earnings Call Transcript Waters Corporation (WAT) Q2 2026 Earnings Call Transcript
- 2026-08-04 Waters (WAT) Q2 Earnings and Revenues Beat Estimates Waters (WAT) came out with quarterly earnings of $3.05 per share, beating the Zacks Consensus Estimate of $3.01 per share. This compares to earnings of $2.95 per share a year ago.
- 2026-08-04 Is Waters Corp (WAT) Holding Value Amidst Q2 Losses? Earnings Beat Estimates with Revenue of $1.645 Billion -- GF Score: 94/100 Waters Corp (WAT) released its 8-K filing on August 4, 2026, presenting a robust performance for the second quarter of 2026 that surpassed analyst expectations
- 2026-08-04 Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results Second Quarter 2026 Highlights Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses. Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.